Physician profile
Ashley Lowe
NPI 1184227761
$3,622.36
in general payments reported to CMS, 2019-2025
26 companies · $946 in 2025
The $946 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $807 · 2023: $700 · 2024: $925 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,434 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,433.76 |
| Education | $136.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $614.74 | 2021-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $498.75 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $351.01 | 2024-2025 | Tremfya, Stelara |
| Pfizer INC. | $342.12 | 2022-2025 | |
| Celgene Corporation | $285.52 | 2022-2024 | Zeposia |
| Genzyme Corporation | $247.95 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $170.13 | 2021-2025 | Rebyota |
| Gilead Sciences, INC. | $140.43 | 2022-2024 | |
| Ethicon US, LLC | $130.14 | 2025 | Linx Reflux Management System |
| Ironwood Pharmaceuticals, INC | $129.57 | 2022-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $93.77 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $80.35 | 2023-2025 | Sucraid |
| Ardelyx, INC. | $70.34 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $58.92 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $56.92 | 2024 | Zymfentra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $50.36 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $49.07 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $48.71 | 2022-2025 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $40.71 | 2025 | Rezdiffra |
| Stryker Corporation | $33.12 | 2025 | Neptune |
| Lilly USA, LLC | $32.01 | 2024-2025 | Omvoh |
| Caris Mpi, INC. | $23.77 | 2025 | Mi Cancer Seek |
| Novo Nordisk INC | $20.84 | 2025 | Wegovy |
| Redhill Biopharma INC. | $20.00 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.99 | 2023 | |
| Vivus LLC | $16.12 | 2025 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.